Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery.

Area of Science:

• Neuroscience
• Molecular Biology
• Biotechnology

Background:

• RNA interference (RNAi) is a powerful tool for gene function research and potential therapy in the central nervous system (CNS).
• Current limitations in safe and efficient small interfering RNA (siRNA) delivery vectors hinder RNAi applications in neurons.
• Cyclodextrins show promise as low-toxicity gene delivery vectors but haven't been used for neuronal oligonucleotide delivery.

Purpose of the Study:

• To synthesize and evaluate a modified beta-cyclodextrin (CD) vector for siRNA delivery into neuronal cells.
• To assess the safety and efficacy of the CD-siRNA nanoparticles in vitro.
• To establish a novel, safe, and effective method for siRNA delivery in the CNS.

Main Methods:

• Synthesis of a modified beta-cyclodextrin (CD) vector.
• Complexation of siRNA with the CD vector to form cationic nanoparticles (<200 nm).
• In vitro evaluation in immortalized hypothalamic and primary hippocampal neurons, assessing siRNA delivery, cell viability, and gene knockdown.

Main Results:

• The CD vector formed stable, serum-resistant nanoparticles with siRNA.
• High levels of intracellular labeled siRNA delivery were achieved in neurons.
• Maintained over 80% cell viability.
• Achieved significant gene knockdown, up to 68% for luciferase and 40% for GAPDH.

Conclusions:

• A modified beta-cyclodextrin (CD) serves as a safe and efficacious vector for siRNA delivery into neuronal cells.
• This represents the first successful use of a modified CD for siRNA delivery in neurons.
• The developed vector holds potential for advancing RNAi-based research and therapeutics in the CNS.